TY - JOUR
T1 - Prevention of bloodstream infections in patients undergoing hemodialysis
AU - Fisher, Molly
AU - Golestaneh, Ladan
AU - Allon, Michael
AU - Abreo, Kenneth
AU - Mokrzycki, Michele H.
N1 - Funding Information:
Dr. Allon reports receiving personal fees as a consultant for CorMedix. Dr. Allon is also the Editor-in-Chief of American Society of Nephrology open-access journal Kidney360. Dr. Golestaneh reports grant support from the Cardiorenal Society of America, Horizon Pharmaceuticals, and Montefiore Care Management Organization outside of the submitted work. Dr. Mokrzycki reports stock ownership in Abbott Laboratories. Dr. Golestaneh and Dr. Mokrzycki report positions as Clinical Events Committee Members for Spyral Pivotal Hypertension On-Medications and Spyral Pivotal Hypertension Off-Medications, sponsored by Med-tronic. Dr. Abreo and Dr. Fisher have nothing to disclose.
Publisher Copyright:
© 2020 by the American Society of Nephrology.
PY - 2020/1
Y1 - 2020/1
N2 - Bloodstream infections are an important cause of hospitalizations, morbidity, and mortality in patients receiving hemodialysis. Eliminating bloodstream infections in the hemodialysis setting has been the focus of the Centers for Disease Control and Prevention (CDC) Making Dialysis Safer for Patients Coalition and, more recently, the CDC’s partnership with the American Society of Nephrology’s Nephrologists Transforming Dialysis Safety Initiative. The majority of vascular access-associated bloodstream infections occur in patients dialyzing with central vein catheters. The CDC’s core interventions for bloodstream infection prevention are the gold standard for catheter care in the hemodialysis setting and have been proven to be effective in reducing catheter-associated bloodstream infection. However, in the United States hemodialysis catheter-associated bloodstream infections continue to occur at unacceptable rates, possibly because of lapses in adherence to strict aseptic technique, or additional factors not addressed by the CDC’s core interventions. There is a clear need for novel prophylactic therapies. This review highlights the recent advances and includes a discussion about the potential limitations and adverse effects associated with each option.
AB - Bloodstream infections are an important cause of hospitalizations, morbidity, and mortality in patients receiving hemodialysis. Eliminating bloodstream infections in the hemodialysis setting has been the focus of the Centers for Disease Control and Prevention (CDC) Making Dialysis Safer for Patients Coalition and, more recently, the CDC’s partnership with the American Society of Nephrology’s Nephrologists Transforming Dialysis Safety Initiative. The majority of vascular access-associated bloodstream infections occur in patients dialyzing with central vein catheters. The CDC’s core interventions for bloodstream infection prevention are the gold standard for catheter care in the hemodialysis setting and have been proven to be effective in reducing catheter-associated bloodstream infection. However, in the United States hemodialysis catheter-associated bloodstream infections continue to occur at unacceptable rates, possibly because of lapses in adherence to strict aseptic technique, or additional factors not addressed by the CDC’s core interventions. There is a clear need for novel prophylactic therapies. This review highlights the recent advances and includes a discussion about the potential limitations and adverse effects associated with each option.
UR - http://www.scopus.com/inward/record.url?scp=85077727938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077727938&partnerID=8YFLogxK
U2 - 10.2215/CJN.06820619
DO - 10.2215/CJN.06820619
M3 - Review article
C2 - 31806658
AN - SCOPUS:85077727938
SN - 1555-9041
VL - 15
SP - 132
EP - 151
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 1
ER -